PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/00

A2

(11) International Publication Number: WO 00/10551

(43) International Publication Date: 2 March 2000 (02.03.00)

(21) International Application Number: PCT/US99/19167

(22) International Filing Date: 23 August 1999 (23.08.99)

(30) Priority Data:

60/097,665	24 August 1998 (24.08.98)	US
60/099,306	2 September 1998 (02.09.98)	US
Not furnished	11 August 1999 (11.08.99)	US

(71) Applicant: SEPRACOR INC. [US/US]; 111 Locke Drive, Marlborough, MA 01752 (US).

(72) Inventors: JERUSSI, Thomas, P.; 19 Garvey Road, Framingham, MA 01701 (US). SENANAYAKE, Chrisantha, H.; 11 Old Farm Circle, Shrewbury, MA 01545 (US). FANG, Qun, K.; 35 Atwood Street, Wellesley, MA 02181 (US).


(74) Agents: LAWRENCE, Stanton, T., III et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

This Sheet Has Been Replaced



(54) Title: METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS

(57) Abstract

Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive–compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5–HT_3, antagonists.